novel transcript, antisense to FLT1 (ENSG00000298851)

This transcript, designated as novel transcript, antisense to FLT1 (ENSG00000298851), is classified as a long non-coding RNA (lncRNA) transcribed from the strand opposite to the FLT1 gene. Antisense transcripts can regulate the expression of neighboring protein-coding genes (such as FLT1, also known as vascular endothelial growth factor receptor 1 or VEGFR-1) through various mechanisms including transcriptional interference, RNA-RNA binding, or modulation of chromatin states. However, there is currently no direct experimental evidence elucidating the function, targets, or disease roles of ENSG00000298851. It is not a protein-coding gene nor an established therapeutic target[3][1]. Key context: - This entry should not be confused with the protein-coding FLT1 gene product (VEGFR-1), which is a clinically relevant receptor in angiogenesis research[3][1]. - No credible sources classify ENSG00000298851 as an actionable target with drugs or accepted clinical utility. Conclusion: ENSG00000298851 (“novel transcript, antisense to FLT1”) is an uncharacterized lncRNA, not a canonical receptor or drug target. The entry is likely incorrect or incomplete for therapeutic targeting or structured drug database purposes.

Other names

antisense FLT1 RNAFLT1-AS